Skip to main content
Premium Trial:

Request an Annual Quote

Veracyte Amends Loan Agreement

NEW YORK (GenomeWeb) – Veracyte said on Thursday it has amended a loan agreement with Silicon Valley Bank originally forged in June 2013.

Under the terms of the amendment, Veracyte can borrow up to $15 million in three tranches, each tranche not exceeding $5 million. The company borrowed $5 million from the first tranche this week to repay in full the initial $5 million loan drawn in June 2013, the San Francisco-based developer of gene expression-based diagnostic tests said in a document filed with the US Securities and Exchange Commission. 

It can draw on a second tranche of up to $5 million on or before Dec. 31, 2015 and borrow up to another $5 million on or before June 30, 2016.

The firm said that the term loans bear interest at a fixed rate equal to 1.75 percent above the prime rate as published in The Wall Street Journal on the date of incurrence, resulting in the initial $5.0 million term loan bearing interest at a fixed rate of 5 percent.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.